ATE299494T1 - Carbamat-derivate als muscarin-rezeptor antonisten - Google Patents

Carbamat-derivate als muscarin-rezeptor antonisten

Info

Publication number
ATE299494T1
ATE299494T1 AT00983991T AT00983991T ATE299494T1 AT E299494 T1 ATE299494 T1 AT E299494T1 AT 00983991 T AT00983991 T AT 00983991T AT 00983991 T AT00983991 T AT 00983991T AT E299494 T1 ATE299494 T1 AT E299494T1
Authority
AT
Austria
Prior art keywords
derivatives
antonists
carbamat
muscarine receptor
compounds
Prior art date
Application number
AT00983991T
Other languages
English (en)
Inventor
Mathai Mammen
David Oare
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Application granted granted Critical
Publication of ATE299494T1 publication Critical patent/ATE299494T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00983991T 1999-12-07 2000-12-07 Carbamat-derivate als muscarin-rezeptor antonisten ATE299494T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45617099A 1999-12-07 1999-12-07
PCT/US2000/033156 WO2001042212A1 (en) 1999-12-07 2000-12-07 Carbamate derivatives having muscarinic receptor antagonist activity

Publications (1)

Publication Number Publication Date
ATE299494T1 true ATE299494T1 (de) 2005-07-15

Family

ID=41564112

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00983991T ATE299494T1 (de) 1999-12-07 2000-12-07 Carbamat-derivate als muscarin-rezeptor antonisten

Country Status (9)

Country Link
US (1) US7238709B2 (de)
EP (1) EP1235802B1 (de)
JP (1) JP2003516390A (de)
AT (1) ATE299494T1 (de)
AU (1) AU783095B2 (de)
CA (1) CA2392028C (de)
DE (1) DE60021282T2 (de)
MX (1) MXPA02005596A (de)
WO (1) WO2001042212A1 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
NZ537584A (en) 2002-07-08 2006-07-28 Ranbaxy Lab Ltd 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239969B (zh) * 2003-02-14 2011-07-20 施万制药 联苯衍生物
EP1608319A4 (de) 2003-04-03 2007-02-28 Univ California Verbesserte hemmer für lösliche epoxidhydrolase
WO2004089898A1 (en) 2003-04-09 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0409302A (pt) 2003-04-11 2006-04-11 Ranbaxy Lab Ltd derivados azabiciclo como antagonistas de recetores muscarìnicos, método para sua preparação e composição farmacêutica contendo os mesmos
JP2007524641A (ja) * 2003-07-11 2007-08-30 セラヴァンス， インコーポレーテッド 置換４−アミノ−１−ベンジルピペリジン化合物
ES2329586T3 (es) * 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
JP2007528413A (ja) 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087737A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723109A1 (de) 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen
US7262205B2 (en) 2004-03-11 2007-08-28 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723110A1 (de) 2004-03-11 2006-11-22 Theravance, Inc. Als antagonisten des muscarinrezeptors geeignete biphenylverbindungen
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087733A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007532484A (ja) 2004-03-16 2007-11-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法
WO2006023457A1 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
TWI374883B (en) * 2004-08-16 2012-10-21 Theravance Inc Crystalline form of a biphenyl compound
WO2006023460A2 (en) * 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
EP1814875A4 (de) 2004-10-20 2010-02-17 Univ California Verbesserte inhibitoren der löslichen epoxidhydrolase
JP2008521821A (ja) * 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド ムスカリン受容体のモジュレーター
US7629336B2 (en) * 2005-03-10 2009-12-08 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP2008537931A (ja) * 2005-03-10 2008-10-02 セラヴァンス， インコーポレーテッド ムスカリン性レセプターアンタゴニストとして有用なビフェニル化合物
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
EP1866284A1 (de) 2005-03-10 2007-12-19 Theravance, Inc. Biphenylverbindungen als muskarinrezeptorantagonisten
WO2006105035A2 (en) * 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
US7728144B2 (en) * 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1924553A1 (de) * 2005-08-08 2008-05-28 Argenta Discovery Limited Bicyclo[2.2.]hept-7-ylaminderivate und anwendungen davon
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
JP2009519310A (ja) * 2005-12-16 2009-05-14 アージェンタ ディスカバリー リミテッド 環状アミン誘導体およびそれらの使用
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
EP2076261A2 (de) * 2006-10-03 2009-07-08 Ranbaxy Laboratories, Ltd. Muscarinische rezeptor-antagonisten
CA2675942C (en) 2007-02-23 2016-04-12 Theravance, Inc. Quaternary ammonium diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2008133900A1 (en) 2007-04-24 2008-11-06 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
JP5656288B2 (ja) 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
AU2009282525A1 (en) * 2008-08-13 2010-02-18 Wntresearch Ab The use of Wnt5-a peptide derivates for the treatment of melanoma and gastric cancer
PT2599778T (pt) 2009-04-23 2017-06-06 Theravance Respiratory Co Llc Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2
WO2012054093A2 (en) 2010-01-29 2012-04-26 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US9278119B2 (en) 2011-07-01 2016-03-08 Wntresearch Ab Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4587046A (en) 1982-05-18 1986-05-06 The Regents Of The University Of California Drug-carrier conjugates
DE3402060A1 (de) 1984-01-21 1985-08-01 Dr. Karl Thomae Gmbh, 7950 Biberach Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4675326A (en) 1985-05-08 1987-06-23 Gabriel Amitai Bisquaternary antidotes
DK443489D0 (da) 1989-09-08 1989-09-08 Ferrosan As Substituerede urinstofforbindelser, deres fremstilling og anvendelse
PT640081E (pt) * 1992-03-31 2000-05-31 Glaxo Group Ltd Derivados de fenil-carbamatos e fenil-ureias substituidos sua preparacao e sua utilizacao como antagonistas 5-ht4
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
WO1995006635A1 (en) * 1993-09-02 1995-03-09 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
WO1995021820A1 (en) * 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Novel carbamate derivative and medicinal composition containing the same
US5691323A (en) * 1995-05-12 1997-11-25 Merck & Co., Inc. Muscarine antagonists
DE69615214T2 (de) 1995-10-13 2002-06-27 Banyu Pharmaceutical Co., Ltd. Substituierte heteroaromatische derivate
US6500934B1 (en) 1996-07-24 2002-12-31 Michael Rush Lerner Bivalent agonists for G-protein coupled receptors
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
CZ298749B6 (cs) * 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
US5821010A (en) * 1997-02-07 1998-10-13 Eveready Battery Company, Inc. Galvanic cell having a reliable sealable vent closure
EP1047691A1 (de) 1997-12-12 2000-11-02 Smithkline Beecham Plc Chinolinpiperazin- und chinolinpiperidin derivate, deren herstellung und deren verwendung als kombinierte 5-ht1a, 5-ht1b und 5-ht1d rezeptor antagonisten

Also Published As

Publication number Publication date
DE60021282D1 (de) 2005-08-18
EP1235802A1 (de) 2002-09-04
MXPA02005596A (es) 2004-09-10
WO2001042212A1 (en) 2001-06-14
AU2067401A (en) 2001-06-18
DE60021282T2 (de) 2006-05-18
CA2392028A1 (en) 2001-06-14
JP2003516390A (ja) 2003-05-13
AU783095B2 (en) 2005-09-22
US20040029919A1 (en) 2004-02-12
US7238709B2 (en) 2007-07-03
CA2392028C (en) 2009-08-18
EP1235802B1 (de) 2005-07-13

Similar Documents

Publication Publication Date Title
DE60021282D1 (de) Carbamat-derivate als muscarin-rezeptor antonisten
EA200200646A1 (ru) Соединения мочевины, обладающие активностью антагонистов мускариновых рецепторов
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
DE69532162D1 (de) Cannabinoid-rezeptor-antagonisten
DE60335891D1 (de) Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste
DE60131730D1 (de) Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden
TR200201568T2 (tr) İkame edilmiş imidazol nöropeptid Y Y5 reseptörü antagonistleri.
DE60205234D1 (de) 1,2,3,4-tetrahydroisochinolin-derivate als urotensin ii rezeptor-antagonisten
ATE435210T1 (de) Tetrahydroisochinolylacetamidderivate zur verwendung als orexinrezeptorantagonisten
ATE312090T1 (de) 4-(piperidyl- und pyrrolidyl-alkyl-ureido)- chinoline als urotensin ii rezeptor antagonisten
MA29088B1 (fr) Composes d'indazole-carboxamide.
ATE478664T1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
SE0101675D0 (sv) Novel composition
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
YU80902A (sh) Novi indolin-2-on derivati, njihovo dobijanje i farmaceuski oblici koji ih sadrže
ATE334965T1 (de) Piperidinverbindungen als muscarinantagonisten
EA200400467A1 (ru) Производные 3-азабицикло (3.1.0) гексана в качестве антагонистов опиоидного рецептора
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
EA200801184A1 (ru) Производные пипередин-4-ил-пиридазин-3-иламина как быстро диссоциирующие антагонисты рецептора дофамина 2
EP1244452A4 (de) Urotensin-ii rezeptorantagonisten
SE9901077D0 (sv) Novel use
TR200200310T2 (tr) Interlökin-5 inhibe eden 6-azaurasil türevleri.
EA200600688A1 (ru) Арилинденпиридины и арилинденпиримидины и их применение в качестве антагонистов аденозинового рецептора а2а
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
WO2001029066A3 (en) Basic monocyclic compounds having nk2 antagonist action, processes for their preparation, and formulations containing them

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties